Targeted Inactivation of Hepatocyte Growth Factor Receptor C-Met in -Cells Leads to Defective Insulin Secretion and GLUT-2 Downregulation Without Alteration of -Cell Mass

Diabetes - United States
doi 10.2337/diabetes.54.7.2090
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Diabetes Association

Related search

C-Met Proto-Oncogene (MET; HGFR); Hepatocyte Growth Factor/Scatter Factor (HGF/SF)

Science-Business eXchange
2014English

Down-Regulation of MET, the Receptor for Hepatocyte Growth Factor

Oncogene
Cancer ResearchGeneticsMolecular Biology
2001English

PET of C-Met in Cancer With 64Cu-Labeled Hepatocyte Growth Factor

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2015English

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of C-Met and Vascular Endothelial Growth Factor Receptor 2

Clinical Cancer Research
Cancer ResearchOncology
2010English

The N-Terminal Domain of Hepatocyte Growth Factor Inhibits the Angiogenic Behavior of Endothelial Cells Independently From Binding to the C-Met Receptor

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2003English

Cell Cycle Effects Resulting From Inhibition of Hepatocyte Growth Factor and Its Receptor C-Met in Regenerating Rat Livers by RNA Interference

Hepatology
MedicineHepatology
2007English

Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target

Biomarker Insights
BiochemistryMolecular MedicinePharmacology
2017English

Amplification and Overexpression of the Hepatocyte Growth Factor Receptor (HGFR/MET) in Rat DMBA Sarcomas

Oncogene
Cancer ResearchGeneticsMolecular Biology
1999English

Defective Insulin Secretion in Pancreatic Β Cells Lacking Type 1 IGF Receptor

Journal of Clinical Investigation
Medicine
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy